If you’ve been diagnosed with major depressive disorder, seasonal affective depression or any other type of depression, your ...

The largest, most ethnically diverse, study of its kind has flagged hundreds of genetic variants that play a role in ...

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...

However, in people with mild cognitive impairment, the presence of depressive symptoms was tied to a lower likelihood of amyloid pathology (OR 0.73, 95% CI 0.61-0.89, P =0.001), Oomens and colleagues ...

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...

Johnson & Johnson has announced a major breakthrough in mental health treatment. The Food and Drug Administration (FDA) has approved Spravato, a novel nasal spray, for the standalone treatment of ...

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...

The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.

A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral antidepressants. On Tuesday, the Food and Drug Administration (FDA) ...